Trial Profile
Validation of Predictors for Oral Anticoagulant Medication Choice Using EMR Data
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Mar 2019
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Stroke; Thromboembolism
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 13 Jun 2017 Status changed from recruiting to completed.
- 30 May 2017 Planned End Date changed from 15 May 2017 to 5 Jun 2017.
- 30 May 2017 Planned primary completion date changed from 15 May 2017 to 5 Jun 2017.